PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

Jonel Trebicka(Goethe University Frankfurt), Javier Fernández(European Foundation for the Study of Chronic Liver Failure), Mária Papp(University of Debrecen), Paolo Caraceni(University of Bologna), Wim Laleman(KU Leuven), Carmine Gambino(University of Padua), Ilaria Giovo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Frank Erhard Uschner(Goethe University Frankfurt), Christian Jansen(University Hospital Bonn), César Jiménez(Universitat Autònoma de Barcelona), Rajeshwar P. Mookerjee(The Royal Free Hospital), Thierry Gustot(Erasmus Hospital), Agustı́n Albillos(Universidad de Alcalá), Rafael Bañares(Hospital General Universitario Gregorio Marañón), Peter Jarčuška(University of Pavol Jozef Šafárik), Christian J. Steib(LMU Klinikum), Thomas Reiberger(Medical University of Vienna), Juan Acevedo(University Hospitals Plymouth NHS Trust), Pietro Gatti, Debbie L. Shawcross(King's College Hospital), Stefan Zeuzem(Goethe University Frankfurt), Alexander Zipprich, Salvatore Piano(University of Padua), Thomas Berg(Leipzig University), Tony Bruns(Universitätsklinikum Aachen), Karen Vagner Danielsen(University of Copenhagen), Minneke J. Coenraad(Leiden University Medical Center), Manuela Merli(Sapienza University of Rome), Rudolf Stauber(Medical University of Graz), Heinz Zoller(Innsbruck Medical University), José Presa Ramos(Association for the Development of Douro Viticulture), Cristina Solé(Centro de Investigación Biomédica en Red), Germán Soriano(Hospital de Sant Pau), Andrea De Gottardi(University Hospital of Bern), Henning Grønbæk(Aarhus University Hospital), Faouzi Saliba(Inserm), Christian Trautwein(Universitätsklinikum Aachen), Haluk Tarık Kani(Marmara University), Sven Francque(Antwerp University Hospital), Stephen Ryder(Nottingham University Hospitals NHS Trust), Pierre Nahon(Inserm), Manuel Romero‐Gómez(Hospital Universitario Virgen del Rocío), Hans Van Vlierberghe(Ghent University Hospital), Claire Francoz(Inserm), Michael P. Manns(Medizinische Hochschule Hannover), Elisabet García(European Foundation for the Study of Chronic Liver Failure), Manuel Tufoni(University of Bologna), Àlex Amorós(European Foundation for the Study of Chronic Liver Failure), Marco Pavesi(European Foundation for the Study of Chronic Liver Failure), Cristina Sánchez(European Foundation for the Study of Chronic Liver Failure), Michael Praktiknjo(University Hospital Bonn), Anna Curto(European Foundation for the Study of Chronic Liver Failure), Carla Pitarch(European Foundation for the Study of Chronic Liver Failure), Antonella Putignano(Erasmus Hospital), Esau Moreno(European Foundation for the Study of Chronic Liver Failure), William Bernal(King's College Hospital), Ferrán Aguilar(European Foundation for the Study of Chronic Liver Failure), Joan Clària(European Foundation for the Study of Chronic Liver Failure), Paola Ponzo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Zsuzsanna Vitális(University of Debrecen), Giacomo Zaccherini(University of Bologna), Boglárka Balogh(University of Debrecen), Alexander L. Gerbes(LMU Klinikum), Vı́ctor Vargas(Universitat Autònoma de Barcelona), Carlo Alessandria(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Mauro Bernardi(University of Bologna), Pere Ginès(Centro de Investigación Biomédica en Red), Richard Moreau(Inserm), Paolo Angeli(University of Padua), Rajiv Jalan(The Royal Free Hospital), Vicente Arroyo(European Foundation for the Study of Chronic Liver Failure), Miriam Maschmeier(European Foundation for the Study of Chronic Liver Failure), David Semela(Goethe University Frankfurt), Laure Elkrief(University Hospital Bonn), Ahmed M. Elsharkawy(Hospital Clínic de Barcelona), Tamás Tornai(University of Debrecen), István Tornai(University of Debrecen), I Altorjay(University of Debrecen), Agnese Antognoli(University of Bologna), Maurizio Baldassarre(University of Bologna), Martina Gagliardi(University of Bologna), Eleonora Bertoli(University of Padua), Sara Mareso(Association for the Development of Douro Viticulture), Alessandra Brocca(University of Padua), Daniela Campion(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Giorgio Maria Saracco(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Martina Rizzo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Jennifer Lehmann(Universitat Autònoma de Barcelona), Alessandra Pohlmann(Universitat Autònoma de Barcelona), Maximilian Joseph Brol(Universitat Autònoma de Barcelona), Johannes Chang(Universitat Autònoma de Barcelona), Robert Schierwagen(Goethe University Frankfurt), Elsa Solà(The Royal Free Hospital), Nesrine Amari(Erasmus Hospital), Miguel Ángel Morán Rodríguez(Universidad de Alcalá), Frederik Nevens(KU Leuven), Ana Clemente(European Foundation for the Study of Chronic Liver Failure), Martin Janíčko(University of Pavol Jozef Šafárik), Daniel Markwardt(University of Copenhagen), Mattias Mandorfer(Medical University of Vienna), Christoph Welsch(Goethe University Frankfurt), T Welzel(Goethe University Frankfurt), Emanuela Ciracì, Vish Patel(King's College Hospital), Cristina Ripoll(European Foundation for the Study of Chronic Liver Failure), Adam Herber(Leipzig University), Paul Horn(Jena University Hospital), Flemming Bendtsen(European Foundation for the Study of Chronic Liver Failure), Lise Lotte Gluud(University of Copenhagen), Jelte J. Schaapman(University of Copenhagen), Oliviero Riggio(Sapienza University of Rome), Florian Rainer(Medical University of Graz), Jörg Tobiasch Moritz(Innsbruck Medical University), Mónica Mesquita(Association for the Development of Douro Viticulture), Edilmar Alvarado‐Tápias(Hospital de Sant Pau), O Akpata(University Hospital of Bern), Luise Aamann(Aarhus University Hospital), Didier Samuel(Inserm), Sylvie Tresson(Inserm), Pavel Strnad(Inserm), Roland Amathieu(European Foundation for the Study of Chronic Liver Failure), Macarena Simón‐Talero(Antwerp University Hospital), Francois Smits(Erasmus Hospital), Natalie Van den Ende(European Foundation for the Study of Chronic Liver Failure), Javier Martínez(European Foundation for the Study of Chronic Liver Failure), Rita García‐Martínez(European Foundation for the Study of Chronic Liver Failure), Harald Rupprechter(European Foundation for the Study of Chronic Liver Failure), Cornelius Engelmann(Medical University of Vienna), Osman Özdoğan(Nottingham University Hospitals NHS Trust)
Journal of Hepatology
November 20, 2020
Cited by 284Open Access
Full Text

Abstract

BACKGROUND & AIMS: Acute decompensation (AD) of cirrhosis may present without acute-on-chronic liver failure (ACLF) (AD-No ACLF), or with ACLF (AD-ACLF), defined by organ failure(s). Herein, we aimed to analyze and characterize the precipitants leading to both of these AD phenotypes. METHODS: The multicenter, prospective, observational PREDICT study (NCT03056612) included 1,273 non-electively hospitalized patients with AD (No ACLF = 1,071; ACLF = 202). Medical history, clinical data and laboratory data were collected at enrolment and during 90-day follow-up, with particular attention given to the following characteristics of precipitants: induction of organ dysfunction or failure, systemic inflammation, chronology, intensity, and relationship to outcome. RESULTS: Among various clinical events, 4 distinct events were precipitants consistently related to AD: proven bacterial infections, severe alcoholic hepatitis, gastrointestinal bleeding with shock and toxic encephalopathy. Among patients with precipitants in the AD-No ACLF cohort and the AD-ACLF cohort (38% and 71%, respectively), almost all (96% and 97%, respectively) showed proven bacterial infection and severe alcoholic hepatitis, either alone or in combination with other events. Survival was similar in patients with proven bacterial infections or severe alcoholic hepatitis in both AD phenotypes. The number of precipitants was associated with significantly increased 90-day mortality and was paralleled by increasing levels of surrogates for systemic inflammation. Importantly, adequate first-line antibiotic treatment of proven bacterial infections was associated with a lower ACLF development rate and lower 90-day mortality. CONCLUSIONS: This study identified precipitants that are significantly associated with a distinct clinical course and prognosis in patients with AD. Specific preventive and therapeutic strategies targeting these events may improve outcomes in patients with decompensated cirrhosis. LAY SUMMARY: Acute decompensation (AD) of cirrhosis is characterized by a rapid deterioration in patient health. Herein, we aimed to analyze the precipitating events that cause AD in patients with cirrhosis. Proven bacterial infections and severe alcoholic hepatitis, either alone or in combination, accounted for almost all (96-97%) cases of AD and acute-on-chronic liver failure. Whilst the type of precipitant was not associated with mortality, the number of precipitant(s) was. This study identified precipitants that are significantly associated with a distinct clinical course and prognosis of patients with AD. Specific preventive and therapeutic strategies targeting these events may improve patient outcomes.


Related Papers

No related papers found

Powered by citation graph analysis